Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-blind, Double-dummy, Placebo-controlled, Randomized, Three Parallel Groups Study Comparing the Efficacy, Safety and Tolerability of Pramipexole ER Versus Placebo and Versus Pramipexole IR Administered Orally Over a 26-week Maintenance Phase in Patients With Early Parkinsons Disease (PD).

NCT00479401 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT00479401
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00479401 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-blind, Double-dummy, Placebo-controlled, Randomized, Three Parallel Groups Study Comparing the Efficacy, Safety and Tolerability of Pramipexole ER Versus Placebo and Versus Pramipexole IR Administered Orally Over a 26-week Maintenance Phase in Patients With Early Parkinsons Disease (PD).
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Completed
Start date
May 31, 2007
Completion date
Not reported
Enrollment
539 (actual)
Sites
95

Conditions

As the registry lists them; a condition with its own page is linked.

early parkinson disease (early pd)